Negative Regulators of Hemopoiesis and Stroma Function in Patients with Myelodysplastic Syndrome

References

• Mayer R. J., Canellos G. P. Primary myelodysplastic syndrome and secondary preleukemic disorders. Leukemia, E. S. Henderson, T. A. Lister, M. F. Greaves. W.B. Saunders Company, Philadelphia 1996; 513–534
   Google Scholar
• Noel P., Solberg L. A., Jr. Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment. Crit Rev Oncol Hematol 1992; 12: 193–215
   PubMed Web of Science ®Google Scholar
• Hatake K., Tomizuka H., Ikeda M., Tsunoda J., Hoshino Y., Ohtsuki T., Kasahara T., Yonehara S., Miura Y. The presence of apoptosis in refractory anemia of myelodysplasia. Molecular Biology of Haematopoiesis, N. Abraham, R. K. Shadduck, A. S. Levine, F. Takaku. Intercept Ltd., AndoverUK 1994; 127–133
   Google Scholar
• Bogdanovic A. D., Jankovic G. M., Colovic M. D., Trpinac D. P., Bumbasirevic V. Z. Apoptosis in bone marrow of myelodysplastic syndrome patients [letter]. Blood 1996; 87: 3064–3064
   PubMed Web of Science ®Google Scholar
• Raza A., Gezer S., Mundle S., Gao X. Z., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A., Loew J., Marcus B., Khan Z., Chaney C., Showel J., Gregory S., Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268–276
   PubMed Web of Science ®Google Scholar
• Rajapaksa R., Ginzton N., Rott L. S., Greenberg P. L. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88: 4275–4287
   PubMed Web of Science ®Google Scholar
• Shetty V., Mundle S., Alvi S., Showel M., Broady-Robinson L., Dar S., Borok R., Showel J., Gregory S., Rifkin S., Gezer S., Parcharidou A., Venugopal P., Shah R., Hernandez B., Klein M., Alston D., Robin E., Dominquez C., Raza A. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 1996; 20: 891–900
   PubMed Web of Science ®Google Scholar
• Raza A., Gezer S., Gregory S. A., Venugopal P., Kaizer H., Dong L. M., Span L., Hines C., Thomas R., Alvi S., Mundle S. D., Shetty V., Borok R., Loew J., Reza S., Robin E. L., Rifkin S. D., Alston D., Hernandez B. M., Shah R., Hsu W.-T., Dar S., Preisler H. D. Anti-cytokine therapy produces responses in patients with myelodysplastic syndromes (MDS). Blood 1996; 88: 580a
   PubMedGoogle Scholar
• Raza A., Mundle S., Shetty V., Alvi S., Chopra H., Span L., Parcharidou A., Dar S., Venugopal P., Borok R., Gezer S., Showel J., Loew J., Robin E., Rifkin S., Alston D., Hernandez B., Shah R., Kaizer H., Gregory S., Preisler H. A paradigm shift in myelodysplastic syndromes. Leukemia 1996; 10: 1648–1652
   PubMed Web of Science ®Google Scholar
• Maciejewski J., Selleri C., Anderson S., Young N. S. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis fac-tor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995; 85: 3183–3190
   PubMed Web of Science ®Google Scholar
• Gersuk G. M., Beckham C., Loken M. R., Kiener P., Anderson J. E., Farrand A., Troutt A. B., Ledbetter J. A., Deeg H. J. A role for tumor necrosis factor-α, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103: 176–188
   PubMed Web of Science ®Google Scholar
• Terstappen L. W., Safford M, Konemann S., Loken M. R., Zurlutter K., Buchner T., Hiddemann W., Wormann B. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 1992; 6: 70–80
   PubMed Web of Science ®Google Scholar
• Shulman H. M., Wells D., Gooley T., Myerson D., Bryant E., Loken M. R. The biologic significance of rare peripheral blasts after hematopoietic cell transplant is predicted by multidimensional flow cytometry. Am J Clin Pathol., (in press)
   Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C., The French-American-British (FAB) Co-Operative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199
   PubMed Web of Science ®Google Scholar
• Greenberg P., Cox C., LeBeau M. M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Srour E. F., Brandt J. E., Briddell R. A., Grigsby S., Leemhuis T., Hoffman R. Long-term generation and expansion of human primitive hematopoietic progenitor cells in vitro. Blood 1993; 81: 661–669
   PubMed Web of Science ®Google Scholar
• Greinix H. T., Storb R., Bartelmez S. H. Specific growth inhibition of primitive hematopoietic progenitor cells mediated through monoclonal antibody binding to major histocompatibility class II molecules. Blood 1992; 80: 1950–1956
   PubMed Web of Science ®Google Scholar
• Stelzer G. T., Shults K. E., Loken M. R. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann NY Acad Sci 1993; 677: 265–280
   PubMed Web of Science ®Google Scholar
• Loken M. Multidimensional data analysis in immunophenotyping. Current Protocols in Cytometry, J. P Robinson. Wiley, New York 1997
   Google Scholar
• Sievers E. L., Lange B. J., Buckley J. D., Smith F. O., Wells D. A., Daigneault-Creech C. A., Shults K. E., Bernstein I. D., Loken M. R. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 1996; 88: 1483–1488
   PubMed Web of Science ®Google Scholar
• Sutherland H. J., Lansdorp P. M., Henkelman D. H., Eaves A. C., Eaves C. J. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci USA 1990; 87: 3584–3588
   PubMed Web of Science ®Google Scholar
• Reems J. A., Torok-Storb B. Cell cycle and functional differences between CD34+/CD38hi and CD34+/38lo human marrow cells after in vitro cytokine exposure. Blood 1995; 85: 1480–1487
   PubMed Web of Science ®Google Scholar
• Dexter T. M., Allen T. D., Lajtha L. G. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977; 91: 335–344
   PubMed Web of Science ®Google Scholar
• Verfaillie C. M. Direct contact between human primitive hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis. Blood 1992; 79: 2821–2826
   PubMed Web of Science ®Google Scholar
• Tanaka M., Suda T., Haze K., Nakamura N., Sato K., Kimura R, Motoyoshi K., Mizuki M., Tagawa S., Ohga S., Hatake K., Drummond A. H., Nagata S. Fas ligand in human serum. Nat Med 1996; 2: 317–322
   PubMed Web of Science ®Google Scholar
• Yamaguchi M., Nadler S., Lee J.-W., Deeg H. J. Induction of negative regulators of hematopoiesis in human bone marrow cells by HLA-DR crosslinking. Transpl Immunol., (in press)
   Web of Science ®Google Scholar
• Lee J. W., Gersuk G. M., Kiener P. A., Beckham C., Ledbetter J. A., Deeg H. J. HLA-DR-triggered inhibition of hemopoiesis involves Fas/Fas ligand interactions and is prevented by c-kit ligand. J Immunol 1997; 159: 3211–3219
   PubMed Web of Science ®Google Scholar
• Gersuk G. M., Lee J. W., Beckham C. A., Anderson B., Deeg H. J. Fas (CD95) receptor and fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome (letter). Blood 1996; 88: 1122–1123
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Appelbaum F. R., Fisher L. D., Schoch G., Shulman H., Anasetti C., Bensinger W. I., Bryant E., Buckner C. D., Doney K., Martin P. J., Sanders J. E., Sullivan K. M., Thomas E. D., Witherspoon R. P., Hansen J. A., Storb R. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677–681
   PubMed Web of Science ®Google Scholar
• Hong D.-S., Beckham C., Huss R., Lee J. W., Hockenbery D., Ledbetter J. A., Deeg H. J. Major histocompatibility complex class II-mediated inhibition of hematopoiesis in long-term marrow cultures involves apoptosis and is prevented by c-kit ligand. Blood 1995; 86: 3341–3352
   PubMed Web of Science ®Google Scholar
• Span L. F., Dar S. E., Shetty V., Mundle S. D., Broady-Robinson L., Alvi S., Raymakers R. A., De Witte T., Raza A. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia. Leukemia 1998; 12: 1685–1695
   PubMed Web of Science ®Google Scholar
• Oosterveld M., Suciu S., Rodts P., Belhabri A., Aul C., Ferrant A., Muus P., De Witte T. J.M. Peripheral blood stem cell (PSC) mobilization after chemotherapy in patients with high risk myelodysplastic syndrome. An ongoing prospective European multicenter study supported by Biomed II. Leuk Res 1999; 23: S84, Supplement I, (#218). Fifth International Symposium on Myelodysplastic Syndromes, Prague, Czech Republic, 21–24 April 1999
   Google Scholar
• Loken M., Wells D. A. (in press) Normal antigen expression in hematopoiesis: Basis for interpreting leukemia pheno-types. Immunophenotyping, C. Stewart, J. Nicholson. Wiley Liss, New York
   Google Scholar